The aim of this study was to describe the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis after SARS-CoV-2 vaccination.

This trial tested the safety and efficacy of levosimendan in improving supine slow vital capacity after 12 weeks of treatment in 496 people with amyotrophic lateral sclerosis.

In this article the authors describe structural changes in cerebral small vessels of patients with COVID-19 and elucidate potential mechanisms underlying the vascular pathology.

Study to define the prevalence of neurological conditions among hospitalized patients with a positive SARS-CoV-2 reverse transcription polymerase chain reaction test in geographically diverse multinational populations.

In this study, the authors built on their previous publication using a new, larger cohort to investigate whether they could reproduce previous findings while addressing some of the prior study's limitations.

In this study, the authors assessed cognitive profiles and regional cerebral glucose metabolism as a biomarker of neuronal function in outpatients suffering from long-term neurocognitive symptoms after COVID-19.

The purpose of this study was to determine the frequency of brain lesion patterns on brain MRI in SARS-CoV-2 pneumonia patients who developed focal and non-focal neurological manifestations.

In this article the authors aimed to evaluate the impact of the COVID-19 pandemic on patient-reported health outcomes after hospital admission for acute stroke.

This systematic review and meta-analysis aims to explore the characteristics of ischemic stroke after SARS-CoV-2 infection, and provides valuable reference materials for subsequent clinical treatment.

Case series/case reports (Indigo) In March 2020, the United Kingdom Multiple Sclerosis Register (UKMSR) established an electronic case return form, designed collaboratively by MS neurologists, to record data about COVID-19 infections in people with MS (pwMS). The objective of this… Continue Reading

In a prospective cross-sectional study, the authors determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects.

Our beloved EAN colleague Eveline Sipido has been closely involved in organised neurology for the past few decades. This conversation was an opportunity to delve into her memories of the development of the EAN and its forerunners.

EAN President, Claudio Bassetti provides a general update and insights into the EAN’s current activities and priorities.

A report on the the 12th Regional Teaching Course in sub-Saharan Africa, held virtually and hosted at Makerere University, Kampala, Uganda, on 10-11 September 2021.

In this single-center prospective case study the authors report patients with neurological autoimmunity in temporal association (≤6 weeks) with SARS-CoV-2 vaccinations and without other triggers.